+

WO1993011798A1 - Formulations ameliorees avec agent d'amelioration de la penetration hydrophobe - Google Patents

Formulations ameliorees avec agent d'amelioration de la penetration hydrophobe Download PDF

Info

Publication number
WO1993011798A1
WO1993011798A1 PCT/US1992/010944 US9210944W WO9311798A1 WO 1993011798 A1 WO1993011798 A1 WO 1993011798A1 US 9210944 W US9210944 W US 9210944W WO 9311798 A1 WO9311798 A1 WO 9311798A1
Authority
WO
WIPO (PCT)
Prior art keywords
glycerol
active agent
sodium
permeation enhancer
sorbitan
Prior art date
Application number
PCT/US1992/010944
Other languages
English (en)
Inventor
Eun Soo Lee
Su Il Yum
Michel J-N. Cormier
Original Assignee
Alza Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corporation filed Critical Alza Corporation
Publication of WO1993011798A1 publication Critical patent/WO1993011798A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Definitions

  • This invention pertains to the transdermal delivery of active agents and more particularly to novel methods and compositions for improving the permeation activity of hydrophobic permeation enhancers.
  • hydrophobic permeation enhancers can be solved by co-delivering a hydrophobic enhancer with a solvent carrier such as propylene glycol, ethanol, isopropyl alcohol or other small molecules which can solubilize the hydrophobic enhancers.
  • a solvent carrier such as propylene glycol, ethanol, isopropyl alcohol or other small molecules which can solubilize the hydrophobic enhancers.
  • irritation problems to the host are frequently encountered.
  • compositions which provide accelerated partitioning of hydrophobic permeation enhancers into the skin or mucosa while exhibiting little or no irritation to the skin. More particularly, the invention is directed to compositions containing a hydrophobic permeation enhancer, which permeation enhancer has been micronized and stabilized in an inert carrier such as water. These compositions can be combined with a biologically active agent to provide enhanced permeability of the active agent to the skin or mucosa. The invention is also directed to active agent formulations containing and active agent together with a micronized hydrophobic permeation enhancer and having enhanced permeability to the skin or mucosa.
  • the invention is additionally directed to a system which comprises a carrier or matrix adapted to be placed in active agent- and permeation enhancer-transmitting relation to a selected skin or other body site.
  • the carrier or matrix contains sufficient amounts of active agent and permeation enhancer to continuously coadminister to the site, over a predetermined delivery period, the active agent, in a therapeutically effective amount, and the hydrophobic permeation enhancer, in an amount effective to enhance the permeation of the skin to the active agent.
  • the invention is further directed to methods for making and using the compositions, the formulations and the systems of the invention.
  • FIG. 1 is a graph showing the flux of hydrocortisone through epidermis from various glycerol monolaurate compositions falling, under the present invention.
  • FIGS. 2 and 3 are graphs showing the flux of hydrocortisone through epidermis from various cream formulations falling under the present invention.
  • FIG. 2 shows the flux from one donor epidermis and
  • FIG. 3 shows the flux from epidermis of another donor.
  • FIG. 4 is a graph showing the skin blanching (expressed as net value after substraction of the value recorded with untreated skin at a control site) obtained in the presence of two hydrocortisone formulations and a commercial formulation of hydrocortisone valerate.
  • This invention utilizes principles of transdermal drug delivery to provide a novel formulation for effectively utilizing hydrophobic permeation enhancers for the increased permeability of active agents through the skin or mucosa along with reduction of the lag time between application of the active agent and attainment of a therapeutically effective agent flux, with little or no irritation to the host.
  • inert carriers such as water, glycerol and polyethylene glycols with various molecular weights (such as PEG 400)
  • the permeation enhancer can be micronized in the inert carrier to provide particles of from about 0.01 microns to about 1000 microns in diameter.
  • These microparticles can then be stabilized by the addition of a stabilizing agent to provide a composition of micronized and stabilized hydrophobic permeation enhancer (the "permeation enhancer composition" of the invention).
  • the active agent formulation surprisingly provides a greatly increased flux of the active agent with a reduction in the lag time as compared to a formulation utilizing a non-micronized hydrophobic permeation enhancer.
  • the icronization accelerates the skin partitioning of the permeation enhancer as a result of one, or possibly both, of two possible scientific grounds: an increased dissolution rate due to increased surface area of the permeation enhancer (the Noyes Whitney equation) or an increase of thermodynamic activity due to reduced particle size of the permeation enhancer (the Kelvin equation).
  • the resulting accelerated skin partitioning increases the permeation activity of the enhancer while reducing or eliminating the lag time between application to the skin and attainment of a therapeutically effective flux rate. Additionally, because accelerated partitioning can occur in an inert carrier as a result of this invention, use of harmful solvents are not necessary and irritation to the host is therefore avoided.
  • the permeation enhancer composition of the invention is prepared by mechanically or otherwise micronizing a hydrophobic permeation enhancer in an inert carrier such as water by methods generally known in the art.
  • the resulting microparticles of enhancer are from about 0.01 micron to about 1000 microns in diameter, preferably from about 0.1 micron to about 100 microns.
  • a micronization stabilizing agent is then added to maintain the microparticles distributed throughout the carrier solution. Without the stabil zer, the microparticles will precipitate out of solution and the composition will lose its increased permeation-enhancing effectiveness.
  • Permeation enhancers which are useful in the present invention are those enhancers which are hydrophobic so that they are insoluble or only sl ghtly soluble in water or other inert carriers. This includes, but is not limited to, fatty acids of from 10 to 20 carbon atoms, such as oleic acid, lauric acid, myristic acid, stearic acid, linoleic acid, and palmitic acid; mono-, di- and tri-glycerides of C 10 . 20 fatty acids, such as glycerol monolaurate, glycerol monooleate, glycerol dioleate, glycerol trioleate and glycerol monolinoleate; C 10 .
  • fatty acid mono-, di- and tri-esters of sorbitols such as sorbitan monooleate, sorbitan trioleate, and sorbitan monolaurate; isopropyl myr state; sucrose monococoate; and the like.
  • Glycerol monolaurate, glycerol monooleate, and glycerol monolinoleate are presently preferred.
  • the hydrophobic permeation enhancer is present in the composition in a permeation- enhancing amount, that is, in an amount to effectively enhance the permeation of an active agent.
  • the micronization stabilizer is hydrophilic and water soluble and may be selected from, but is not limited to, bile salts such as sodium deoxycholate, sodium cholate, sodium dehydrocholate, and the like; sodium laurate; sodium dodecylsulfate; sodium benzoate; sodium alginate; benzalkonium chloride; Tween 20; Tween 80; polyvinyl alcohol; and other ionic or nonionic surfactants with hydrophilic and lipophilic balance numbers greater than 15.
  • the stabilizer is generally present in the composition in an amount of from about 0.1 wt% to about 5 wt%, preferably from about 0.2 wt% to about 3 wt%.
  • the inert carrier is preferably water, but may also be selected from, for example, glycerol and polyethylene glycols such as PEG 400.
  • the hydrophobic permeation enhancer composition of the present invention may be combined with a biologically active agent to provide enhanced transdermal delivery of the agent.
  • transdermal delivery or application refers to the delivery or application of agents by passage through skin, mucosa and/or other body surfaces by topical application. It is believed that this invention has utility in connection with the delivery of active agents within the broad class normally delivered through body surfaces and membranes, including the skin.
  • active agent is used interchangeably with the term "drug”, and the two expressions are intended to have their broadest interpretation as to any therapeutically active substance, agent, drug, composition of matter or mixture thereof which is delivered to a living organism to produce a desired, usually beneficial, effect. In general, this includes therapeutic agents in all of the major therapeutic areas. Included among the types of agents which meet this description are biocides, sterilization agents, food supplements, nutrients, vitamins, sex sterilants, fertility inhibitors and fertility promoters.
  • the agents include drugs which act on the peripheral nerves, adrenergic receptors, cholinergic receptors, the skeletal muscles, the cardiovascular system, smooth muscles, the blood circulatory system, synoptic sites, neuroeffector junctional sites, endocrine and hormone systems, the immunological system, the reproductive system, the skeletal system, autocoid systems, the alimentary and excretory systems, the histamine system and the central nervous system.
  • Suitable agents may be selected from, for example, proteins, enzymes, hormones, polynucleotides, nucleoproteins, polysaccharides, glycoproteins, M.
  • beneficial agents with which this invention can be utilized are prochlorperazine edisylate, ferrous sulfate, aminocaproic acid, mecamylamine hydrochloride, procainamide hydrochloride, amphetamine sulfate, methamphetamine hydrochloride, benzphetamine hydrochloride, isoproterenol sulfate, phenmetrazine hydrochloride, bethanechol chloride, methacholine chloride, pilocarpine hydrochloride, atropine sulfate, scopolamine bromide, isopropamide iodide, tridihexethyl chloride, phenformin hydrochloride, methylphenidate hydrochloride, theophylline cholinate, ce
  • proteins and peptides which include, but are not limited to, insulin, colchicine, glucagon, thyroid stimulating hormone, parathyroid and pituitary hormones, calcitonin, renin, prolactin, corticotrophin, thyrotropic hormone, follicle stimulating hormone, chorionic gonadotropin, gonadotropin releasing hormone, bovine somatotropin, porcine somatotropin, oxytocin, vasopressin, prolactin, so atostatin, lypressin, pancreozymin, luteinizing hormone, LHRH, interferons, interleukins, growth hormones such as human growth hormone, bovine growth hormone and porcine growth hormone, fertility inhibitors such as the prostaglandins, fertility promoters, growth factors, and human pancreas hormone releasing factor.
  • the active agent can be present in this invention in a wide variety of chemical and physical forms, such as uncharged molecules, molecular complexes, and pharmaceutically acceptable acid addition and base addition salts such as hydrochlorides, hydrobromides, sulfate, laurylate, oleate, and salicylate.
  • acidic compounds salts of metals, amines or organic cations can be used.
  • Derivatives such as esters, ethers and amides can be used.
  • An active agent can be used alone or mixed with other active agents.
  • the lists of active agents recited above are given only to illustrate the types of active agents which are suitable for use in practicing the invention, and are not intended to be exhaustive.
  • the amount of active agent employed in the delivery device will be that amount necessary to deliver a therapeutically effective amount of the agent to achieve the desired result at the site of application. In practice, this will vary depending on the particular agent, the severity of the condition, and the desired effect, as well as the desired rate and duration of release.
  • terapéuticaally effective rate and "therapeutically effective amount” as used herein mean a rate or an amount which provides a therapeutic effect or result.
  • the active agent and the micronized hydrophobic permeation enhancer are typically dispersed within a physiologically compatible matrix or carrier which may be applied directly to the body as an ointment, liquid, lotion, gel, cream, suppository or sublingual or buccal tablet, for example, or they may be administered from a matrix or carrier in a transdermal therapeutic delivery device.
  • a physiologically compatible matrix or carrier which may be applied directly to the body as an ointment, liquid, lotion, gel, cream, suppository or sublingual or buccal tablet, for example, or they may be administered from a matrix or carrier in a transdermal therapeutic delivery device.
  • a physiologically compatible matrix or carrier When used in the form of a l quid, ointment, lotion, cream or gel applied directly to the skin, it is often desirable although not required to occlude the site of administration to prevent evaporation of any volatile components.
  • Such formulations can also contain other components of topical compositions as are known to the art.
  • the formulations may
  • Transdermal therapeutic devices for delivering a wide variety of drugs or other beneficial agents are well known in the art. Typical devices are described in U.S. Pat. Nos. 3,598,122, 3,598,123, 4,286,592, 4,314,557, 4,379,454, 4,559,222 and 4,573,995, for example.
  • the coadministration of an active agent and a micronized hydrophobic permeation enhancer as disclosed herein can be accomplished using transdermal- devices of these kinds.
  • the active agent formulation of the present invention is applied to an area of skin or mucosa as determined by the therapeutic result desired. If it is applied in an ointment, lotion or gel, for example, it is spread onto the area and it can be covered or occluded, although this is not required. If it is applied with a skin patch or other transdermal delivery device, the device is placed on the area of skin or mucosa and is held in place by an adhesive layer or overlay. Once the formulation is placed on the skin, it will begin coadministering the active agent and the permeation enhancer to the wearer so that the active agent is delivered in a therapeutically effective amount without irritation to the wearer.
  • the active agent formulation can be administered to the skin or mucosa from a skin patch or other transdermal delivery device, it is preferably administered to skin or mucosa by direct application to the skin or mucosa in a carrier in the form of an ointment, gel, cream or lotion, for example.
  • the formulation should be designed to deliver the active agent and the micronized hydrophobic permeation enhancer at the necessary release rates.
  • the active agent formulation is a solution, such as a lotion.
  • Gelling agents may be added to provide the active agent formulation as a gel, another preferred embodiment.
  • suitable gelling agents include, for example, hydroxyethylcellulose, hydroxypropyleel1ulose, hydroxypropylmethyleel1ulose, hydroxypropylmethylphthalate, sodium Carbomer ® (sodium salt of polyacrylic acid), and other hydrogel polymers of both hydrophilic and hydrophobic types.
  • Thickening agents may also be utilized, an example of which is Cabosil ® (silicon dioxide).
  • the active agent formulation is a cream.
  • hydrophobic permeation enhancer, stabilizer and inert carrier other additives may be included to provide an active agent cream with enhanced permeation activity. These additives include a humectant and a waxy oil .
  • the humectant may be selected from any of the known humectants which are compatible with the permeation enhancer and the active agent. These include, but are not limited to, glycerol, PEG400, propylene glycol, and the like.
  • the humectant is generally present in the active agent formulation in an amount of from about 5 wt% to about 25 wt%.
  • the waxy oil may be selected from those generally known in the art and includes, but is not limited to, white petrolatum, fats, high molecular weight (i.e., solid or solid-like) organic alcohols, polyglycol esters ⁇ , and the like.
  • the oil phase is generally present in the active agent formulation in an amount of from about 10 wt% to about 60 wt%. This imparts stability and a smooth and velvety feel to the skin surface. It also assists in water retention. Additionally, additives such as cetyl alcohol, stearyl alcohol or any other fatty alcohols may optionally be included in the oil phase to improve the creamy texture of the cream formulation.
  • the active agent is present in the active agent formulation at a concentration at or in excess of saturation or solubility, the amount of excess being a function of the desired length of the agent delivery period.
  • the active agent may, however, be present at a level below saturation without departing from this invention as long as the drug and the permeation enhancer are continuously and co-extensively administered to the same skin or mucosa site in an amount and for a period of time sufficient to obtain the desired therapeutic effect.
  • a hydrocortisone formulation according to this invention was prepared as follows.
  • a first mixture of white petrolatum (35 wt%), glycerol monolaurate (“GML”; 15 wt%), glycerol (12 wt ) and hydrocortisone (0.5 wt%) was heated in a water bath at 80-85'C with stirring until melted.
  • a second mixture containing sodium deoxycholate (1.0 wt%) and water (36.5 wt ), was also heated separately in a water bath at 80-85'C with stirring until melted.
  • the two melts were then combined and allowed to cool, with constant stirring or shaking until the combined mixture was congealed, to give a hydrocortisone cream having contained therein a dispersion of micronized fine solid particles of glycerol monolaurate.
  • formulation A without the sodium deoxycholate as a stabilizer, showed comparable flux to several other of the formulations, formulation A was unstable and the microparticles of GML settled out of solution and onto the bottom of the vessel.
  • the formulations with NaDC all maintained their dispersion of micronized particles of GML regardless of the temperature or other environmental variables.
  • hydrocortisone cream formulations with different stabilizers were prepared following the procedures of Example 1.
  • the formulations are given under Table C below (amounts are in wt%).
  • WPL white petrolatum
  • GML glycerol monolaurate
  • Dermolate® (0.5% hydrocortisone; Schering-Plough Healthcare Products; formulation "Der.”), following the procedures of Example 3, except that the donor loading was 100 mg/1.13 cm 2 and the formulations were tested on each of two different samples of epidermis.
  • the transdermal flux of hydrocortisone through 1.13 cm 2 of epidermis #1 is shown in FIG. 2 and of epidermis #2 is shown in FIG. 3.
  • Dermolate in addition to 0.5% hydrocortisone, also comprises ceteareth-30, cetearyl alcohol, mineral oil, petrolatum, propylene glycol, sodium phosphate and water.
  • hydrocortisone formulations according to the invention were prepared and tested in vivo for blanching response.
  • a commercial hydrocortisone valerate cream, Westcort ® (0.2% hydrocortisone valerate; Westwood-Squibb Pharmaceuticals) was also tested for comparison.
  • Two hydrocortisone cream formulations were prepared following the procedures of Example 1.
  • Formulation Q had the following composition: glycerol monolaurate ("GML”; 25 wt%), sodium deoxycholate (1 wt%), white petrolatum (25 wt%), glycerol (12 wt%), hydrocortisone (0.5 wt%) and water (36.5 wt%).
  • Formulation R was identical to Q except that it contained 25 wt% of glycerol monooleate (“GMO”) rather than glycerol monolaurate.
  • GMO glycerol monooleate
  • Formulations Q and R were tested in vivo in three adult males.
  • 0.10 mL of each formulation was placed in an aluminum cup (1.1 cm 2 ) and applied to the volar forearm of the subjects. After 16 hr, the cups were removed and the sites were washed. At various times thereafter, the sites were observed and the intensity of the vasoconstriction reaction was scored with an electronic instrument, the Minolta Chroma Meter.
  • FIG. 4 illustrates the results, showing the skin blanching, expressed as net value (a* in the L*a*b* system) after substraction of the value recorded with untreated skin. Skin blanching was achieved with all three formulations.
  • Westcort cream in addition to hydrocortisone valerate, contains white petrolatum, stearyl alcohol, propylene glycol, amphoteric-9, carbomer-940, sodium phosphate, sodium lauryl sulfate, sorbic acid and water.
  • EXAMPLE 7 A lidocaine formulation according to this invention was prepared and tested as follows.
  • the lidocaine/GMLO dispersion (0.4 g) was absorbed into a polyethylene foam pad of 5.5 cm 2 diameter size. The pad was applied on the forearm of an adult male, with an adhesive occlusive overlay, for 35 minutes and was then removed. The treated skin site was examined for pain by needle penetration with a sterile 21 gauge needle. Prickle sensation was blocked.
  • GML glycerol monolaurate
  • GMO Myverol 18-99K glycerol monooleate
  • GMLO Myverol 18-92K glycerol monolinoleate
  • NaDC sodium deoxycholate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une nouvelle formulation pour l'utilisation efficace d'agents améliorant la pénétration hydrophobe afin d'augmenter la perméabilité d'agents actifs à travers la peau ou une muqueuse et réduire le temps entre le moment d'application de l'agent actif et le moment ou le flux de l'agent a un effet thérapeutique, pratiquement sans irritation pour le sujet. L'invention concerne des compositions contenant un agent améliorant la pénétration hydrophobe, cet agent ayant été conditionné sous forme de particules de l'ordre du micron et stabilisé dans un support inerte tel que l'eau. Ces compositions peuvent être combinées à un agent biologiquement actif pour améliorer la perméabilité de l'agent actif sur la peau ou sur une muqueuse.
PCT/US1992/010944 1991-12-16 1992-12-16 Formulations ameliorees avec agent d'amelioration de la penetration hydrophobe WO1993011798A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80841191A 1991-12-16 1991-12-16
US808,411 1991-12-16
US84281692A 1992-02-27 1992-02-27
US842,816 1992-02-27

Publications (1)

Publication Number Publication Date
WO1993011798A1 true WO1993011798A1 (fr) 1993-06-24

Family

ID=27123124

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/010944 WO1993011798A1 (fr) 1991-12-16 1992-12-16 Formulations ameliorees avec agent d'amelioration de la penetration hydrophobe

Country Status (3)

Country Link
AU (1) AU3326493A (fr)
MX (1) MX9207344A (fr)
WO (1) WO1993011798A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009978A1 (fr) * 1995-09-13 1997-03-20 Morten Sloth Weidner Utilisation d'esters de polyols pour augmenter la biodisponibilite orale de substances medicamenteuses, nouveaux esters et compositions pharmaceutiques les contenant
EP0893120A2 (fr) * 1997-07-25 1999-01-27 Henkel Kommanditgesellschaft auf Aktien Compositions auto-emulsionnantes
EP0735867B1 (fr) * 1994-07-26 2003-05-21 Lavipharm S.A. Dispositif d'administration transdermique contenant un oestrogene
FR2905601A1 (fr) * 2006-09-11 2008-03-14 Innoderm Sarl Utilisation de derives oleiques comme methode et composition favorisant la penetration cutanee des actifs contenus dans les compositions cosmetiques, pharmaceutiques ou dermatologiques.
WO2009143175A2 (fr) * 2008-05-19 2009-11-26 Children's Medical Center Corporation Anesthésie locale spécifique aux cellules sensorielles et anesthésie locale de durée prolongée
WO2009143174A2 (fr) * 2008-05-19 2009-11-26 Children's Medical Center Corporation Stimulateurs de perméation chimique mettant en évidence les blocages nerveux par des toxines
US8952152B2 (en) 2009-03-24 2015-02-10 Proteus S.A. Methods for purifying phycotoxins, pharmaceutical compositions containing purified phycotoxins, and methods of use thereof
US8975268B2 (en) 2013-03-15 2015-03-10 The Children's Medical Center Corporation Neosaxitoxin combination formulations for prolonged local anesthesia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2098865A (en) * 1981-04-06 1982-12-01 Sandoz Ltd Topical pharmaceutical compositions
EP0496316A1 (fr) * 1991-01-19 1992-07-29 Hoechst Aktiengesellschaft Formulation de pour-on pour application d'agents anthelmintiques

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2098865A (en) * 1981-04-06 1982-12-01 Sandoz Ltd Topical pharmaceutical compositions
EP0496316A1 (fr) * 1991-01-19 1992-07-29 Hoechst Aktiengesellschaft Formulation de pour-on pour application d'agents anthelmintiques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Dialog Information Services, File 155, Medline, Dialog accession no. 07981724, Medline accession no. 92119724, Wearley LL: "Recent progress in protein and peptide delivery by noninvasive routes", Crit Rev Ther Drug Carrier Syst 1991, 8 (4) p 331-94 *
Dialog Information Services, File 351, WPIL, Dialog accession no. 008655304, WPI accession no. 91-159331/22, YG NONOGAWA SHOJI: "Drug for external dermal use - contains active drug, e.g. indometha- cin, enveloped in lipid microspheres", JP 3093733, A, 910418, 9122 (Basic) *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0735867B1 (fr) * 1994-07-26 2003-05-21 Lavipharm S.A. Dispositif d'administration transdermique contenant un oestrogene
WO1997009978A1 (fr) * 1995-09-13 1997-03-20 Morten Sloth Weidner Utilisation d'esters de polyols pour augmenter la biodisponibilite orale de substances medicamenteuses, nouveaux esters et compositions pharmaceutiques les contenant
EP0893120A2 (fr) * 1997-07-25 1999-01-27 Henkel Kommanditgesellschaft auf Aktien Compositions auto-emulsionnantes
EP0893120A3 (fr) * 1997-07-25 2001-10-24 Henkel Kommanditgesellschaft auf Aktien Compositions auto-emulsionnantes
FR2905601A1 (fr) * 2006-09-11 2008-03-14 Innoderm Sarl Utilisation de derives oleiques comme methode et composition favorisant la penetration cutanee des actifs contenus dans les compositions cosmetiques, pharmaceutiques ou dermatologiques.
WO2009143174A3 (fr) * 2008-05-19 2011-03-24 Children's Medical Center Corporation Stimulateurs de perméation chimique mettant en évidence les blocages nerveux par des toxines
WO2009143174A2 (fr) * 2008-05-19 2009-11-26 Children's Medical Center Corporation Stimulateurs de perméation chimique mettant en évidence les blocages nerveux par des toxines
WO2009143175A3 (fr) * 2008-05-19 2010-10-28 Children's Medical Center Corporation Anesthésie locale spécifique aux cellules sensorielles et anesthésie locale de durée prolongée
WO2009143175A2 (fr) * 2008-05-19 2009-11-26 Children's Medical Center Corporation Anesthésie locale spécifique aux cellules sensorielles et anesthésie locale de durée prolongée
US8609733B2 (en) 2008-05-19 2013-12-17 Massachusetts Institute Of Technology Sensory-specific local anesthesia and prolonged duration local anesthesia
US8658699B2 (en) 2008-05-19 2014-02-25 Massachusetts Institute Of Technology Chemical permeation enhancers enhance nerve blockade by toxins
US8952152B2 (en) 2009-03-24 2015-02-10 Proteus S.A. Methods for purifying phycotoxins, pharmaceutical compositions containing purified phycotoxins, and methods of use thereof
US8957207B2 (en) 2009-03-24 2015-02-17 Proteus S.A. Methods for producing phycotoxins
US9249150B2 (en) 2009-03-24 2016-02-02 Proteus S.A. Methods for purifying phycotoxins, pharmaceutical compositions containing purified phycotoxins, and methods of use thereof
US8975268B2 (en) 2013-03-15 2015-03-10 The Children's Medical Center Corporation Neosaxitoxin combination formulations for prolonged local anesthesia
US8975281B2 (en) 2013-03-15 2015-03-10 The Children's Medical Center Corporation Neosaxitoxin combination formulations for prolonged local anesthesia
US10314833B2 (en) 2013-03-15 2019-06-11 The Children's Medical Center Corporation Neosaxitoxin combination formulations for prolonged local anesthesia
US10881647B2 (en) 2013-03-15 2021-01-05 The Children's Medical Center Corporation Neosaxitoxin combination formulations for prolonged local anesthesia

Also Published As

Publication number Publication date
MX9207344A (es) 1993-07-01
AU3326493A (en) 1993-07-19

Similar Documents

Publication Publication Date Title
US5629019A (en) Formulations with hydrophobic permeation enhancers
AU778889B2 (en) Novel topical oestroprogestational compositions with systemic effect
KR100445449B1 (ko) 아실락틸레이트를사용한피부침투증진제조성물
TW200526252A (en) Surfactant-based gel as an injectable, sustained drug delivery vehicle
JP2930623B2 (ja) 医薬活性剤の経皮デリバリー用組成物
US8221784B2 (en) Transdermal hormone delivery system: compositions and methods
JP2660839B2 (ja) 局所塗布用浸透促進製薬組成物
CA2439120C (fr) Polymeres erodables a injecter
EP1183010A2 (fr) Compositions de gel implantables et procede de fabrication
CA2360300C (fr) Composition transdermique d'un agent antiemetique et preparation contenant cette composition
EP0393727A2 (fr) Système à délivrance transdermique
NO338665B1 (no) Doseringssystem med kontrollert frigivning for nasale anvendelser
JPH06502429A (ja) 経皮避妊製剤、方法及びデバイス
WO1993011798A1 (fr) Formulations ameliorees avec agent d'amelioration de la penetration hydrophobe
WO2002045685A2 (fr) Composites a base de polymeres cristallisables/non cristallisables
CZ2002488A3 (cs) Transdermální podávání lasofoxifenu
JPS62223119A (ja) 外用クリ−ム製剤
CN1886100A (zh) 基于表面活性剂的凝胶作为可注射的持续药物递送载体
EP1949890A2 (fr) Compositions de gel implantables et procédé de fabrication

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA FI JP KR NO NZ

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)

Free format text: EUROPEAN PATENT(MC)

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载